



(51) International Patent Classification:
C12N 5/10 (2006.01)

(21) International Application Number:
PCT/IB2015/001203

(22) International Filing Date:
17 March 2015 (17.03.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/954,337 17 March 2014 (17.03.2014) US

(71) Applicant: FOUNTAIN BIOPHARMA INC.; 19F-1, No. 3, Yuan Qu St, Nangang District, Taipei, 115 (TW).

(72) Inventors; and

(71) Applicants : CHEN, Nien-Yi; 4F., No. 54, Ln. 700, Zongzheng Rd, Xindian Dist., New Taipei City, 23150 (TW). WU, Che-Haorz; 3F.No.4, Ln. 25, Zhongzheng Rd, Banqiao Dist, New Taipei City, 23150 (TW). CHEN, Hung-Chi; 19F-1, No.3, Yuan Qu St., Nangang District, Taipei, 115 (TW). TOWN, Winston [CA/—]; 5F, No.3, Sec. 1, Dunhau S. Rd., Songshan Dist., Taipei City, 105 (TW).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS FOR PRODUCING RECOMBINANT GLYCOPROTEINS WITH MODIFIED GLYCOSYLATION

Figure 3

A.



(57) Abstract: Genetically engineered host animal cells capable of producing glycoproteins having modified glycosylation patterns, e.g., defucosylation and/or monoglycosylation. Such host animal cells can be engineered to express fucosidase, endoglycosidase or both.

